Kathleen I. Pritchard

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Retrieved on: 
Thursday, May 20, 2021

"Exact Sciences is changing the way we detect and treat cancer.

Key Points: 
  • "Exact Sciences is changing the way we detect and treat cancer.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Retrieved on: 
Wednesday, May 19, 2021

"Exact Sciences is changing the way we detect and treat cancer.

Key Points: 
  • "Exact Sciences is changing the way we detect and treat cancer.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.

City of Hope Scientists Have Developed a Precision Medicine Tool That Predicts If Chemotherapy Will Produce Debilitating Side Effects in Older Adults

Retrieved on: 
Thursday, January 14, 2021

(Photo credit: City of Hope)

Key Points: 
  • (Photo credit: City of Hope)
    This first-of-its-kind risk assessment tool called the Cancer and Aging Research Group-Breast Cancer (CARG-BC) Score helps oncologists make personalized treatment recommendations.
  • Oncologists can discuss the score and its significance with early-stage breast cancer patients age 65 or older.
  • Though chemotherapy is an effective way to treat early-stage breast cancer, it also carries a risk of side effects.
  • As a next step, the researchers will look to improve the chemotherapy toxicity risk assessment tool with more biological markers.

Breast Cancer Index™ demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients

Retrieved on: 
Thursday, December 17, 2020

San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight session on December 9that this years San Antonio Breast Cancer Symposium.

Key Points: 
  • San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight session on December 9that this years San Antonio Breast Cancer Symposium.
  • The Investigation on the Duration of Extended Adjuvant Letrozole (IDEAL) trial examined the Breast Cancer Index (BCI) HOXB13/IL17BR (H/I) ratio and its ability to predict benefit from extended endocrine therapy.
  • The Breast Cancer Index (BCI) allows us to sort out the patients who will benefit from extended endocrine therapy from those who will not (but who will suffer the harms).
  • Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early stage, HR+ breast cancer.

New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice

Retrieved on: 
Friday, December 11, 2020

These data highlight the role of the test in further individualizing treatment decisions in early breast cancer.

Key Points: 
  • These data highlight the role of the test in further individualizing treatment decisions in early breast cancer.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

Retrieved on: 
Wednesday, December 9, 2020

RxPONDER showed a different effect of chemotherapy based on Recurrence Score results for postmenopausal and premenopausal women.

Key Points: 
  • RxPONDER showed a different effect of chemotherapy based on Recurrence Score results for postmenopausal and premenopausal women.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

Retrieved on: 
Wednesday, December 9, 2020

RxPONDER showed a different effect of chemotherapy based on Recurrence Score results for postmenopausal and premenopausal women.

Key Points: 
  • RxPONDER showed a different effect of chemotherapy based on Recurrence Score results for postmenopausal and premenopausal women.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.

Novartis' MONALEESA-7 KISQALI® (ribociclib) study demonstrated statistically significant improvement in overall survival in pre- and perimenopausal women with HR+/HER2- advanced breast cancer

Retrieved on: 
Monday, November 2, 2020

"Overall survival is considered a very important outcome in oncology clinical trials," said Dr. Nathaniel Bouganim, Medical Oncologist, McGill University Health Centre.

Key Points: 
  • "Overall survival is considered a very important outcome in oncology clinical trials," said Dr. Nathaniel Bouganim, Medical Oncologist, McGill University Health Centre.
  • "The new ribociclib data showing overall survival benefit in the most common type of breast cancer in young women is an exciting and significant step towards meeting the most urgent unmet need for these women."
  • "We are pleased to make yet another strong medical data announcement around KISQALI and its potential for overall survival benefit."
  • Canadian Breast Cancer Network and Rethink Breast Cancer.

Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance

Retrieved on: 
Friday, October 30, 2020

Veracyte, Inc ., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Journal of Clinical Oncology (JCO).

Key Points: 
  • Veracyte, Inc ., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Journal of Clinical Oncology (JCO).
  • Results suggest that the genomic underpinnings of Veracytes Prosigna Breast Cancer Gene Signature Assay, particularly the tests relative weighting of genes predicting tumor proliferation, may explain the classifiers previously demonstrated, higher likelihood of predicting long-term risk of recurrence among certain breast cancer patients, compared to other breast cancer tests.
  • The study compared the commercial forms of four breast cancer recurrence-risk tests: the PAM50-based Prosigna Risk of Recurrence (ROR), the Oncotype DX Risk Score (RS), EndoPredict (EP) and Breast Cancer Index (BCI).
  • Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Biotheranostics’ Breast Cancer Index IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors

Retrieved on: 
Thursday, October 29, 2020

San Diego, CA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast Cancer Index (BCI) and predictive evidence in patients treated with aromatase inhibitors.

Key Points: 
  • San Diego, CA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast Cancer Index (BCI) and predictive evidence in patients treated with aromatase inhibitors.
  • With practice changing data from the IDEAL study, BCI clinical evidence for endocrine prediction has been demonstrated in three distinct therapy groups - patients treated with Tamoxifen/Tamoxifen, Tamoxifen/Aromatase Inhibitor and now, for the first time, Aromatase Inhibitor/Aromatase Inhibitor.
  • Consistent performance across multiple studies supports the comprehensive clinical utility of BCI in extended endocrine therapy decision-making, agnostic to background therapy with tamoxifen or aromatase inhibitors.
  • Don Hardison, Biotheranostics President and CEO adds, We are thrilled that the Breast Cancer Index IDEAL study has been published in Clinical Cancer Research.